内分泌科用治療薬の世界市場2018-2022

【英語タイトル】Global Endocrinology Drugs Market 2018-2022

Technavioが出版した調査資料(IRTNTR23904)・商品コード:IRTNTR23904
・発行会社(調査会社):Technavio
・発行日:2018年9月19日
・ページ数:117
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後24時間以内)
・調査対象地域:グローバル、アジア、北米、ヨーロッパ(EMEA)
・産業分野:医療・バイオ
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,500 ⇒換算¥518,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD4,000 ⇒換算¥592,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD5,000 ⇒換算¥740,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
当調査レポートでは、内分泌科用治療薬の世界市場について調査・分析し、市場概要、市場環境、内分泌科用治療薬市場規模、治療領域別(糖尿病治療薬、甲状腺ホルモン障害薬、hGH、テストステロン補充療法)分析、市場動向、競争環境、主要地域別市場規模(北米、ヨーロッパ、アジアなど)、関連企業情報などを含め、以下の構成でお届け致します。主な分析対象企業は、Abbvie, Merck, Novo Nordisk, Pfizerなどです。
・エグゼクティブサマリー
・調査範囲・調査手法
・内分泌科用治療薬の世界市場概要
・内分泌科用治療薬の世界市場環境
・内分泌科用治療薬の世界市場動向
・内分泌科用治療薬の世界市場規模
・内分泌科用治療薬の世界市場:業界構造分析
・内分泌科用治療薬の世界市場:治療領域別(糖尿病治療薬、甲状腺ホルモン障害薬、hGH、テストステロン補充療法)
・内分泌科用治療薬の世界市場:地域別市場規模・分析
・内分泌科用治療薬の北米市場規模・予測
・内分泌科用治療薬のヨーロッパ・中東・アフリカ市場規模・予測
・内分泌科用治療薬のアジア太平洋市場規模・予測
・内分泌科用治療薬の主要国分析
・内分泌科用治療薬の世界市場:意思決定フレームワーク
・内分泌科用治療薬の世界市場:成長要因、課題
・内分泌科用治療薬の世界市場:競争環境
・内分泌科用治療薬の世界市場:関連企業情報(ベンダー分析)
【レポートの概要】

About Endocrinology Drugs
Endocrinology is a branch of biology and medicine concerned with the study of the endocrine system. Endocrine disorders include diabetes, thyroid hormone disorders, and sexual dysfunction.
Technavio’s analysts forecast the Global Endocrinology Drugs Market to grow at a CAGR of 6.48% during the period 2018-2022.

Covered in this report
The report covers the present scenario and the growth prospects of the endocrinology drugs market. To calculate the market size, the report considers the revenue generated from the sales of endocrinology drugs.

Technavio’s report, endocrinology drugs market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Key vendors
• Abbvie
• Merck
• Novo Nordisk
• Pfizer

Market driver
• Increase in patient awareness
• For a full, detailed list, view our report
Market challenge
• Shortage of endocrinologists
• For a full, detailed list, view our report

Market trend
• Use of biosimilars for endocrine disorders
• For a full, detailed list, view our report

Key questions answered in this report
• What will the market size be in 2022 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 05: PIPELINE ANALYSIS
• Pipeline analysis
PART 06: MARKET SIZING
• Market definition
• Market sizing 2017
• Market size and forecast 2017-2022
PART 07: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 08: MARKET SEGMENTATION BY THERAPY AREA
• Segmentation by therapy area
• Comparison by therapy area
• Diabetes drugs – Market size and forecast 2017-2022
• Thyroid hormone disorder drugs – Market size and forecast 2017-2022
• hGH – Market size and forecast 2017-2022
• Testosterone replacement therapy – Market size and forecast 2017-2022
• Others – Market size and forecast 2017-2022
• Market opportunity by therapy area
PART 09: CUSTOMER LANDSCAPE
PART 10: REGIONAL LANDSCAPE
• Geographical segmentation
• Regional comparison
• Americas – Market size and forecast 2017-2022
• EMEA – Market size and forecast 2017-2022
• APAC – Market size and forecast 2017-2022
• Market opportunity
PART 11: DECISION FRAMEWORK
PART 12: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 13: MARKET TRENDS
• Association between obesity and endocrine disorders
• Use of biosimilars for endocrine disorders
PART 14: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 15: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Abbvie
• Merck
• Novo Nordisk
• Pfizer
PART 16: APPENDIX
• List of abbreviations

Exhibit 01: Parent market
Exhibit 02: Global pharmaceutical drugs market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Pipeline molecules for diabetes
Exhibit 06: Pipeline molecules for hGH
Exhibit 07: Pipeline molecules for other endocrine disorders
Exhibit 08: Market definition – Inclusions and exclusions checklist
Exhibit 09: Market size 2017
Exhibit 10: Validation techniques employed for market sizing 2017
Exhibit 11: Annual global sales of leading endocrine disorder products 2015-2017
Exhibit 12: Global endocrinology drugs market – Market size and forecast 2017-2022 ($ bn)
Exhibit 13: Global endocrinology drugs market – Year over year growth 2018-2022 (%)
Exhibit 14: Five forces analysis 2017
Exhibit 15: Five forces analysis 2022
Exhibit 16: Bargaining power of buyers
Exhibit 17: Bargaining power of suppliers
Exhibit 18: Threat of new entrants
Exhibit 19: Threat of substitutes
Exhibit 20: Threat of rivalry
Exhibit 21: Market condition – Five forces 2017
Exhibit 22: Global endocrinology drugs market by therapy area – Market share 2017-2022 (%)
Exhibit 23: Comparison by therapy area
Exhibit 24: Diabetes drugs – Market size and forecast 2017-2022 ($ bn)
Exhibit 25: Diabetes drugs – Year over year growth 2018-2022 (%)
Exhibit 26: Thyroid hormone disorder drugs – Market size and forecast 2017-2022 ($ bn)
Exhibit 27: Thyroid hormone disorder drugs – Year over year growth 2018-2022 (%)
Exhibit 28: hGH – Market size and forecast 2017-2022 ($ bn)
Exhibit 29: hGH – Year over year growth 2018-2022 (%)
Exhibit 30: Testosterone replacement therapy – Market size and forecast 2017-2022 ($ bn)
Exhibit 31: Testosterone replacement therapy – Year over year growth 2018-2022 (%)
Exhibit 32: Others – Market size and forecast 2017-2022 ($ bn)
Exhibit 33: Others – Year over year growth 2018-2022 (%)
Exhibit 34: Market opportunity by therapy area
Exhibit 35: Customer landscape
Exhibit 36: Global endocrinology drugs market by region – Market share 2017-2022 (%)
Exhibit 37: Regional comparison
Exhibit 38: Endocrinology drugs market in Americas – Market size and forecast 2017-2022 ($ bn)
Exhibit 39: Endocrinology drugs market in Americas – Year over year growth 2018-2022 (%)
Exhibit 40: Top 3 countries in Americas
Exhibit 41: Endocrinology drugs market in EMEA – Market size and forecast 2017-2022 ($ bn)
Exhibit 42: Endocrinology drugs market in EMEA – Year over year growth 2018-2022 (%)
Exhibit 43: Top 3 countries in EMEA
Exhibit 44: Endocrinology drugs market in APAC – Market size and forecast 2017-2022 ($ bn)
Exhibit 45: Endocrinology drugs market in APAC – Year over year growth 2018-2022 (%)
Exhibit 46: Top 3 countries in APAC
Exhibit 47: Market opportunity
Exhibit 48: Vendor landscape
Exhibit 49: Landscape disruption
Exhibit 50: Vendor classification
Exhibit 51: Market positioning of vendors
Exhibit 52: Abbvie overview
Exhibit 53: Abbvie – Business segments
Exhibit 54: Abbvie – Organizational developments
Exhibit 55: Abbvie – Geographic focus
Exhibit 56: Abbvie – Segment focus
Exhibit 57: Abbvie – Key offerings
Exhibit 58: Merck overview
Exhibit 59: Merck – Business segments
Exhibit 60: Merck – Organizational developments
Exhibit 61: Merck – Geographic focus
Exhibit 62: Merck – Segment focus
Exhibit 63: Merck – Key offerings
Exhibit 64: Novo Nordisk overview
Exhibit 65: Novo Nordisk – Business segments
Exhibit 66: Novo Nordisk – Organizational developments
Exhibit 67: Novo Nordisk – Geographic focus
Exhibit 68: Novo Nordisk – Segment focus
Exhibit 69: Novo Nordisk – Key offerings
Exhibit 70: Pfizer overview
Exhibit 71: Pfizer – Business segments
Exhibit 72: Pfizer – Organizational developments
Exhibit 73: Pfizer – Geographic focus
Exhibit 74: Pfizer – Segment focus
Exhibit 75: Pfizer – Key offerings



【掲載企業】

Abbvie, Merck, Novo Nordisk, Pfizer

★調査レポート[内分泌科用治療薬の世界市場2018-2022] (コード:IRTNTR23904)販売に関する免責事項を必ずご確認ください。
★調査レポート[内分泌科用治療薬の世界市場2018-2022]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆